Cancer Center In India Research Articles

How prepared the radiotherapy centers are to deal with COVID-19 pandemic? A nationwide survey from 46 cancer centers across India.

Managing of radiotherapy department in many cancer centers in India has become very challenging during the COVID-19 pandemic. A radiotherapy center has to deal with multiple problems such as long treatment duration of each patient, high caseload on each radiotherapy machine, a limited number of qualified technical staff available, and equipment maintenance. For the department's smooth running, both the patient and healthcare worker must be safe from contacting COVID-19. A robust and planned strategy is required for prevention, screening, and awareness among all. To access our preparedness and evolve by gaining from other radiotherapy centers, a study was conducted using questionnaires and responses collected from different cancer centers in India.

Breaking bad news to patients: A qualitative study of views of patients' relatives

BACKGROUND: In India, relatives do not want to disclose the diagnosis to patient. The aim of this study is to know what are the views, beliefs, and concerns of patients' relatives about disclosure of the diagnosis and prognosis to patients.MATERIALS AND METHODS: The study was conducted at a tertiary cancer center in India. It was a qualitative research with grounded theory approach to study and understand the matrix of information sharing to cancer patients by the caregiving family members. Information was collected by asking to answer a questionnaire in their own language, which was transcribed to English language. This has been certified and approved by the hospital ethics committee.RESULTS: Fifteen eligible and consenting participants of patients' relatives were recruited during their first visit to the outpatient clinic. Patients were selected randomly from the age group of 18 to 60 years having cancer but without having any metabolic diseases. Although 93.3% of the patients were eager to know the information, only 20% of the relatives wanted to disclose diagnosis and 33.3% wanted to disclose all information to patients. Most of the relatives were concerned about the psychological breakdown and depression of patients.CONCLUSION: Several apprehensions were expressed by relatives regarding breaking bad news (BBN). The importance of BBN to patients in relation to enhance the trust between doctor and patient relationships and to improve the quality of life of patients should be conveyed to relatives, to assure them for improving better patient care.

Clinico - demographic profile of hepatoblastoma: An experience from a tertiary care cancer center in India

Clinico - demographic profile of hepatoblastoma: An experience from a tertiary care cancer center in India

Psychosocial factors influencing distress among cancer patients in South India

Abstract Background: The increase of cancer rates in India over the last decade has placed a significant psychosocial burden on patients and their families. To address the psychosocial issues, cancer centers in India have integrated psychosocial services into cancer care by routinely measuring the distress of patients and responding to their distress. In this study, we sought to determine the association between self-reported distress and patient demographic and clinical variables and awareness of their diagnosis and prognosis. Methods: The Department of Psycho-oncology conducted a cross-sectional, cohort study of patients who were being treated for a variety of cancers in a comprehensive cancer center in Chennai, India. Cancer patients (N = 2019) completed a standardized measure of distress and participated in a clinical interview during their admission to a ward or at the time of referral to psycho-oncology. The level of distress was measured by the NCCN Distress Thermometer and problem list. Chi-square tests were used to examine variations in overall distress. Multi-nominal logistic regression analyses were used to assess the level of patients’ reported distress as a function of clinical characteristics (stage of cancer, awareness of diagnosis and prognosis, physical symptoms). Results: The majority (60.3%) of the sample reported a moderate to high level of emotional distress. There were significant associations (P < .05) of younger age, awareness of diagnosis, prognosis, sleep issues, and physical pain with higher levels of distress. Patients who were aware of their diagnoses were more likely to report moderate (P < .01) or severe distress (P < .05) than those who were unaware. Patients who were aware of their prognoses were less likely to report moderate distress (P < .001) and severe distress (P < .001. Implications for Practice and Research: Given that a majority of patients rated at or above the clinical cut-off for distress, oncology centers in India need to provide training for professional psycho-oncology clinicians and incorporate psycho-oncology services to adequately address patients’ distress. Qualitative research may be needed to advance our understanding of specific social and cultural factors that may influence the psychosocial challenges faced by patients. Further investigation of patient distress related to diagnostic disclosure may be helpful in informing practice.

Real-World Outcome of Platinum-Based Chemotherapy in Advanced Breast Cancer (ABC): A Retrospective Study from a Tertiary Cancer Center in India

Abstract Introduction There is a paucity of data on platinum-based chemotherapy in advanced breast cancer (ABC) from developing countries like India. Objectives The objectives were to analyze the efficacy and safety of platinum-based chemotherapy in patients with ABC. Materials and Methods This was a retrospective study of 35 patients with ABC who were treated with platinum-based chemotherapy (gemcitabine and carboplatin, [GC]) in a tertiary cancer center in India from August 2015 to November 2019. The inclusion criteria were patients with ABC, who had received palliative chemotherapy with GC. The exclusion criteria were patients who had received less than two cycles of GC and patients who received platinum-based chemotherapy for neuroendocrine carcinoma of the breast. Results The median age was 45 years (range: 28–68 years). All patients were female (97%) except one male (3%). The histology was ductal carcinoma (77%), mixed (17%), and others (6%). Out of the 12 patients tested for breast cancer (BRCA) gene mutation, six patients had a BRCA mutation. Patients with metastatic and locally progressive disease were 91 and 9%, respectively. The median number of prior lines of systemic therapy for metastatic disease was 1 (range: 0–5). The median number of sites of metastasis was 2 (range: 0–5). Patients with visceral crises were 23%. The median number of cycles of GC chemotherapy received was 6 (range: 2–6). A dose reduction in chemotherapy was done in 74%. The responses among 34 evaluable patients were complete response (11%), partial response (24%), stable disease (41%), and progressive disease (24%). Grade 3 or more hematological and nonhematological toxicities were observed in 69 and 9%, respectively. The median progression-free survival and overall survival were 6 and 8 months, respectively. The 1-year progression-free survival and overall survival were 19 and 34%, respectively. Multivariate analysis showed that patients who had received more than 3 cycles had a better outcome. Conclusion GC was an active and well-tolerated regimen in ABC regardless of the receptor status. Further prospective randomized studies are warranted to assess the optimal regimen in patients with triple-negative breast cancer.

Clinical characteristics, laboratory parameters and outcomes of COVID-19 in cancer and non-cancer patients from a tertiary Cancer Centre in India.

BackgroundThere is paucity of data regarding clinical characteristics, laboratory parameters and outcomes of coronavirus disease (COVID‐19) in cancer versus non‐cancer patients, particularly from India.Materials and MethodsThis was an observational, single‐centre, retrospective analysis of patients with laboratory‐confirmed COVID‐19 hospitalised in our institution between 22 May 2020 and 1 December 2020. We compared baseline clinical characteristics, laboratory parameters and outcomes of COVID‐19 (overall mortality, time to discharge) between cancer and non‐cancer patients.ResultsA total of 200 COVID‐19 infection episodes were analysed of which 109 (54.5%) were patients with cancer and 91 (45.5%) were patients without cancer. The median age was 43 (interquartile range [IQR]:32–57), 51 (IQR: 33–62) and 38 (IQR: 31.5–49.3) years; of whole cohort, cancer and non‐cancer patients, respectively. Comparison of outcomes showed that oxygen requirement (31.2% [95% CI: 22.6–40.7] vs. 17.6% [95% CI: 10.4–26.9]; p = 0.03), median time to discharge (11 days [IQR: 6.75–16] vs. 6 days [IQR: 3–9.75]; p < 0.001) and mortality (10.0% [95% CI: 5.2–17.3] vs. 1.1% [95% CI: 0.03–5.9]; p = 0.017) were significantly higher in patients with cancer. In univariable analysis, factors associated with higher mortality in the whole cohort included diagnosis of cancer (10.1% vs. 1.1%; p = 0.027; odds ratio [OR]: 7.04), age ≥60 (17.4% vs. 2.6%; p = 0.001; OR: 7.38), oxygen requirement (22% vs. 0.6%; p < 0.001; OR: 29.01), chest infiltrates (19.2% vs. 1.4%; p < 0.001; OR: 22.65), baseline absolute lymphocyte count <1 × 109/L (10.8% vs. 1.9%; p = 0.023; OR:5.1), C‐reactive protein >1 mg% (12.8% vs. 0%; p = 0.027; OR: 24.69), serum procalcitonin >0.05 ng/ml (22.65% vs. 0%; p = 0.004; OR: 4.49) and interleukin‐6 >6 pg/ml (10.8% vs. 1.3%; p = 0.036; OR: 3.08). In multivariable logistic regression, factors significantly associated with mortality were oxygen requirement (p = 0.005; OR: 13.11) and high baseline procalcitonin level (p = 0.014; OR: 37.6).ConclusionCancer patients with COVID‐19 have higher mortality and require longer hospital stay. High procalcitonin levels and oxygen requirement during admission are other factors that affect outcomes adversely.

Diffuse Large B-Cell Lymphoma in the Elderly : Retrospective Analysis from a Single Tertiary Cancer Center in India

IntroductionDiffuse large B-cell lymphoma (DLBCL) commonly affects the elderly population and the treatment is often challenging because of the close interplay between age, comorbidities, frailty as well as cognitive and psychosocial factors. Anthracycline constitutes the cornerstone of the treatment regimen of Non-Hodgkin lymphoma but is associated with several side-effects including cardiotoxicity. At our institute, we replace doxorubicin with etoposide in cases where compromised cardiac function, performance status (PS) and multiple comorbidities are major concerns. We aim to retrospectively analyze the treatment outcomes of patients with DLBCL aged ≥ 60 years and specifically compare R-CHOP and R-CEOP regimens.MethodsIn this retrospective study, we included patients aged ≥ 60 years, newly diagnosed with DLBCL according to WHO classification between January 2015 to December 2018 at our center. Chemotherapy regimens received included R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone), R-CE (Etoposide) OP for anthracycline-ineligible or elderly frail patients and R-EPOCH, followed by radiotherapy for residual disease or bulky sites (size > 7cm). The decision to use anthracycline or non-anthracycline based regimen was at the discretion of the physician depending on the performance status, frailty and serum albumin levels. Dose of etoposide used in the R-CEOP regimen was 65mg/m 2 orally on day 1-3. Primary G-CSF prophylaxis was used in all patients. After 4 cycles of chemotherapy, patients underwent an interim PET-CT for response evaluation. Patients who attained partial response underwent a repeat PET-CT evaluation at the end of 6 cycles. Post treatment completion, patients were followed up for clinical examination every three months for the first two years, six monthly for the next three years and annually thereafter.ResultsA total of 218 patients were included. The median age of patients was 65 years (range, 60-88 years). Patients were divided into two age-groups with 124 patients (56.9%) of the age group of 60-65 years and 94 patients (43.1%) were aged above 65 years. Of the 218 patients, 71 patients (32.6%) received R-CHOP regimen and 137 patients (62.4%) received R-CEOP regimen, while 10 patients (5.0%) received R-EPOCH. More patients aged >65 years received R-CEOP than in the 60-65 years age group (83% vs 47.6%) and the difference was statistically significant (p-value <0.001). Reasons for replacing doxorubicin were cardiac contraindications (9.6%), presence of hypertension or ≥ 2 significant comorbidities (29.9%), advanced age (age ≥ 75 years, 8.0%), baseline Eastern Cooperative Oncology Group (ECOG) PS of > 2 (3.6%), and physician's discretion in 48.9% of cases. Baseline disease characteristics including NCCN-IPI of patients treated with both these regimens were comparable. Complete response rate and overall response rate were higher in the R-CHOP group compared to the R-CEOP group, but statistically significant difference was found only among 60-65 years of age group. Among patients aged 60-65 years, the incidence of febrile neutropenia and grade III/IV hematological toxicities were significantly higher in the R-CHOP group than in the R-CEOP group. The overall median follow-up was 22.71 months (Range 1-81 months). The 2-year progression-free survival (PFS) rate in the R-CHOP group was higher than that in the R-CEOP group (79.1% vs 49.6%, p-value <0.001) (Figure 1). This statistically higher 2-year PFS rate was found among patients with early as well as advanced stage disease, and also in the age group of 60-65 years (Figure 2, 3). Match pairing analysis after adjusting for confounders like NCCN-IPI and presence of bulky disease showed significantly higher 2-year PFS rate in the R-CHOP group than in the R-CEOP group (70.0% vs 34.6%, p-value <0.001). ECOG PS at presentation, NCCN-IPI and the chemotherapy regimen were found to be significant factors for PFS by multivariate analysis (Table 1).ConclusionAge and comorbidities are not absolute contraindications to the use of anthracyclines. Fit patients without cardiac contraindications should receive R-CHOP regimen whenever possible. Geriatric assessment tools should be used for the frail or unfit patients to guide appropriate therapy and further prospective trials should be done in this direction. [Display omitted] DisclosuresNo relevant conflicts of interest to declare.

Outcome of Breast Cancer Patients with COVID-19 Infection: A Report from a Tertiary Cancer Center in India

Background: Nowadays breast cancer (BC) is the most common cancer in women. More than 1.5 million cases are detected yearly. Survival of patients is dependent on several factors. Metastasis and cancer recurrence of different types and in different locations have various outcome. Methods: This is a retrospective cohort study to describe survival of patients after diagnosis of breast cancer based on receptor subtypes and sites of metastasis among Iranian population. A total number of 2051 females with breast cancer were evaluated and among these, 138 patients with recurrent BC were investigated. Results: The 1-year survival of local, bone, visceral and brain metastasis were 64.99%, 63%, 32.83%, and 21.57%, respectively. Based on sites of metastasis, bone and local metastasis showed the best survival while brain and visceral metastasis had the worst survival and prognosis. Conclusion: Our study showed that Her2 enriched positive BCs had the worst survival, this may be due to Trastuzumab uncovered insurance till 10 years ago in our country. Also, drugs related to luminal A and B which are used to improve their survival and hormonal therapy could be associated with their better prognosis in comparison to triple negative receptor subtype. But this study showed that triple negative BC had better survival.

Unique challenges and outcomes of young women with breast cancers from a tertiary care cancer centre in India

BackgroundYoung (≤40 years) breast cancers (YBC) are uncommon, inadequately represented in trials and have unique concerns and merit studying. MethodsThe YBC treated with a curative intent between 2015 and 2016 at our institute were analysed. ResultsThere were 1228 patients with a median age of 36 (12–40) years; 38 (3.1%) had Stage I, 455 (37.1%) - II, 692 (56.3%) –III, and remaining 43 (3.5%) Stage IV (oligo-metastatic) disease; 927 (75.5%) were node positive; 422 (34.4%) were Triple negatives (TNBC), 331 (27%) were HER-2 positive. There were 549 (48.2%) breast conservations and 591 (51.8%) mastectomies of which 62 (10.4%) underwent breast reconstruction. 1143 women received chemotherapy, 617 (53.9%) received as neoadjuvant and 142 (23.1%) had pathological complete response; 934 (81.9%) received adjuvant radiotherapy. At the median follow-up of 48 (0–131) months, 5-year overall and disease-free survival was 79.6% (76.8–82.5) and 59.1% (55.8–62.6). For stage I, II, III and IV, the 5-year overall-survival was 100%, 86.7% (82.8–90.6), 77.3% (73.4–81.2), 69.7% (52.5–86.9) and disease-free survival was 94% (85.9–100), 65.9% (60.3–71.5), 55% (50.5–59.5), and 29.6% (14–45.2) respectively. On multivariate analysis, TNBC and HER-2+ subgroups had poorer survival (p = 0.0035). 25 patients had BRCA mutations with a 5-year DFS of 65.1% (95% CI:43.6–86.6). Fertility preservation was administered in 104 (8.5%) patients; seven women conceived and 5 had live births. Significant postmenopausal symptoms were present in 153 (13%) patients. ConclusionMore than half of the YBC in India were diagnosed at an advanced stage with aggressive features leading to suboptimal outcomes. Awareness via national registry and early diagnosis is highly warranted. Menopausal symptoms and fertility issues are prevalent and demand special focus.

P05.05 Impact of Lung Stereotactic Body Radiotherapy on Pulmonary Function Test – Experience from Tertiary Cancer Centre in India

Stereotactic body radiotherapy (SBRT) has proven to be an effective modality for medically inoperable early-stage non-small cell lung cancer (ES-NSCLC) and pulmonary metastases. However, the concern remains of its effect on pulmonary function test parameters especially in patients with chronic obstructive pulmonary disease (COPD).

P39.02 Does Neo-Adjuvant Chemotherapy Help in Locally Advanced Thymic Maliganancy?

Neoadjuvant chemotherapy is used to downsize thymic malignancies and improve R0 resection. However, there is no level I evidence for this. Here, we present our experience with neoadjuvant chemotherapy for locally advanced thymomas from a tertiary cancer center in India. This is a retrospective analysis of a prospective database. (Jan05 to Dec20) We included the following patients receiving neoadjuvant chemotherapy: Unresectable: Involving aortic arch / branches, main pulmonary trunk, heart Borderline Resectable: Involving SVC, brachiocephalic vein, main PA / branches, lung parenchyma Volumetric analysis was done using “ellipsoid” method for tumor volumes. Survival analysis was performed with Kaplan Meier method. Forty-one patients received neoadjuvant chemotherapy. At presentation, 16(41.5%) were unresectable, 25(56.1%) were borderline resectable. Most common structures at risk were arch aorta and branches(31.7%), SVC(24.39%) and main Pulmonary Artery(19.51%). Average tumor volume was 655.75cm3(90.45 – 4212.0) Good proportion of patients completed the planned chemotherapy(90.24%). However, only 56.1% came up for surgery. 4 progressed, 2 died due to chemotherapy related toxicity, 3 refused surgery and 9 remained unresectable. 12.5% of unresectable tumors and 44.0% of borderline tumors underwent R0 resection. 3/41 patients had complications Clavien-Dindo 3b and above with 1 mortality. The best volume reduction was seen in thymoma B2(54.84%) and thymic carcinomas(42.02%). At a median follow up of 34 months, 3 patients had local and 2 had systemic recurrences. Patients with R0 resection did significantly better than those with R+ resections or found unresectable.(p=0.03) R0 resectability remains the most important predictor of survival in thymic neoplasms. Neoadjuvant chemotherapy introduces the possibility of R0 reaction in unresectable tumors and should be strongly considered. In borderline resectable tumors, neoadjuvant chemotherapy affords a higher rate of R0 resection with less complex resections and minimal morbidity. This finding should be further evaluated in prospective multi centric studies

ICG-Based Sentinel Lymph Node Biopsy in Endometrioid Endometrial Carcinoma—Results of a Prospective Study from a Single Tertiary Cancer Center of India

ICG-Based Sentinel Lymph Node Biopsy in Endometrioid Endometrial Carcinoma—Results of a Prospective Study from a Single Tertiary Cancer Center of India

Building research capacity in India: The Masters in Clinical Research program at the Tata Memorial Centre.

Clinical research is an essential part of evidence-based medicine. The conduct of high-quality clinical research requires the backing of strong infrastructure, especially well-trained clinical research professionals. Tata Memorial Centre is the largest public cancer center in India and has been offering a Masters degree in Clinical Research since 2014. In this article, we look at the need for clinical research training, the evolution of this course and the impact it has had on clinical research capacity in India

Demographics, Pattern of Care, and Outcome Analysis of Malignant Melanomas - Experience From a Tertiary Cancer Centre in India.

BackgroundTreatment of malignant melanoma has undergone a paradigm shift with the advent of immune checkpoint inhibitors (ICI) and targeted therapies. However, access to ICI is limited in low-middle income countries (LMICs).Patients and MethodsHistologically confirmed malignant melanoma cases registered from 2013 to 2019 were analysed for pattern of care, safety, and efficacy of systemic therapies (ST).ResultsThere were 659 patients with a median age of 53 (range 44–63) years; 58.9% were males; 55.2% were mucosal melanomas. Most common primary sites were extremities (36.6%) and anorectum (31.4%). Nearly 10.8% of the metastatic cohort were BRAF mutated. Among 368 non-metastatic patients (172 prior treated, 185 de novo, and 11 unresectable), with a median follow-up of 26 months (0–83 months), median EFS and OS were 29.5 (95% CI: 22–40) and 33.3 (95% CI: 29.5–41.2) months, respectively. In the metastatic cohort, with a median follow up of 24 (0–85) months, the median EFS for BSC was 3.1 (95% CI 1.9–4.8) months versus 3.98 (95% CI 3.2–4.7) months with any ST (HR: 0.69, 95% CI: 0.52–0.92; P = 0.011). The median OS was 3.9 (95% CI 3.3–6.4) months for BSC alone versus 12.0 (95% CI 10.5–15.1) months in any ST (HR: 0.38, 95% CI: 0.28–0.50; P < 0.001). The disease control rate was 51.55%. Commonest grade 3–4 toxicity was anemia with chemotherapy (9.5%) and ICI (8.8%). In multivariate analysis, any ST received had a better prognostic impact in the metastatic cohort.ConclusionsLarge real-world data reflects the treatment patterns adopted in LMIC for melanomas and poor access to expensive, standard of care therapies. Other systemic therapies provide meaningful clinical benefit and are worth exploring especially when the standard therapies are challenging to administer.

Pazopanib in rare histologies of metastatic soft tissue sarcoma.

BackgroundUncommon histopathological subtypes account for less than 5% cases of soft tissue sarcoma (STS) and unclassified STSs comprise another 16%, these are often chemotherapy-resistant, with a dismal outcome in unresectable/metastatic disease. Prospective studies on the use of pazopanib in this cohort of patients are lacking in the literature. Here, we describe the safety and efficacy of pazopanib in rare histologies of advanced STS.Materials and methodsWe conducted a retrospective study at two tertiary cancer centres in India, evaluating 33 cases of rare subtypes of STS, who received pazopanib as per institutional protocol between January 2013 and December 2019. Patients who received pazopanib for unresectable/metastatic disease were enrolled in this study for clinicopathologic features, treatment outcome and evaluation of prognostic factors.ResultsOut of 33 patients, there were seven cases of undifferentiated pleomorphic sarcoma, four cases each of myxofibrosarcoma, epithelioid sarcoma and malignant peripheral nerve sheath tumour, three cases each of haemangiopericytoma and spindle cell sarcoma, two cases of haemangioendothelioma and a case each of clear cell sarcoma, retroperitoneal sarcoma, angiosarcoma and pleomorphic rhabdomyosarcoma-adult type. The objective response rate was 27%. Most of the patients (67%) received pazopanib in second or subsequent lines of therapy. The majority (70%) were started at a lower dose of 400/600 mg and only 43% of these (10/23) could be escalated to a full dose of 800 mg based on tolerance. On univariate analysis, pazopanib’s starting dose didn’t predict progression-free survival (PFS)/overall survival (OS)/response rate. At a median duration of follow-up of 18.8 months (range 1.9–150.4 months), the median PFS and median OS were 10.3 months (95% confidence interval (CI): 5.9–14.8) and 17.8 months (95% CI: 10.7–29.3), respectively. 27% of the patients experienced grade ¾ toxicities, 12% required dose modification of pazopanib and 21% needed permanent discontinuation due to toxicity.ConclusionOur study shows that pazopanib is active in rare subtypes of STS.

Relevance of Combined Electron and Photon Beams in Radiotherapy of Head and Neck Cancers in the Era of Intensity-Modulated Radiotherapy

Introduction External beam radiotherapy (EBRT) for head and neck (H&amp;N) cancers continues to be delivered using varied technologies, ranging from the old two-dimensional conventional radiotherapy (2DRT) techniques to the modern three-dimensional conformal radiotherapy (3DCRT), intensity-modulated radiotherapy (IMRT), and volumetric modulated arc therapy (VMAT) in different centers in India. Due to limitations of spinal cord tolerance, electron and photon beams are combined in 2DRT and 3DCRT techniques for treating nodal volume of the H&amp;N cases. However, many centers having modern technology practice IMRT/VMAT in place of electron beams. The purpose of this study is to analyze the role of combined electron and photon beams in radiotherapy of H&amp;N cancers and its relevance in the modern era of IMRT/VMAT.Materials and Methods Data were collected through a survey conducted on cancer centers in India where radiotherapy is being given by 2DRT, 3DCRT, and IMR/VMAT for the treatment of head and neck cancers.Results The mean percentage of H&amp;N (H&amp;N) cases among all cases were 39.2% (standard deviation [SD]: 14.22), out of which 16.63% (SD: 20.83) were treated with a combination of photon and electron beams and 49.73% (SD: 37.41) were treated with IMRT/VMAT. The average percentage of H&amp;N cases of government institutes was 38.39% (SD: 14.11) and that of private institutes was 40.14% (SD: 14.11). Patients treated with photon and electron combination and IMRT/VMAT were 22.19% (SD: 11.24) and 24.05% (SD: 23.99), respectively, in government institutes, and 10.29% (SD: 11.24) and 79.09% (SD: 26.75) in private institutes.Conclusion As per this study, we conclude that despite the availability of IMRT/VMAT, a combination of electron and photon beams is still relevant in India. Since a large proportion of the patients are still treated with the electron and photon combination, it is imperative that further studies on field–junction dosimetry should be conducted to ensure accurate dose delivery.

High dose methotrexate containing regimen in pediatric non-metastatic extremity osteosarcoma patients: experience from a tertiary cancer center in India

Methotrexate containing chemotherapy is less commonly used for treatment of osteosarcoma in resource limited settings. We present our experience with the administration of high dose methotrexate (HDMTX) containing chemotherapy over a period of three years. Children between 1 and 14 years of age with newly diagnosed nonmetastatic extremity osteosarcoma, registered in Pediatric Oncology Department of a tertiary care cancer center in South India between 1st January 2016 and 31st December 2018 and receiving MAP chemotherapy were included. Patients in this study received HDMTX at 12 g/m2. Twenty two patients were included. After neoadjuvant chemotherapy, 20 patients underwent surgery (limb salvage surgery in 16, amputation in 4). The median time from initiation of chemotherapy to surgery was 97.5 days. Eighteen of 22 patients (81.8%) completed planned chemotherapy in our cohort, one patient was lost to follow up after progression and three patients required change of chemotherapy due to toxicities. Of a total of 227 cycles of HDMTX infusions in 22 patients, delayed clearance occurred in 22 cycles (9.7%). Major toxicities were myelosuppression (30 episodes in 17 patients), blood stream infections (24 episodes in 15 patients) and mucositis (15 episodes in 10 patients). Hearing loss was documented in 7 patients. There was no treatment related mortality. Chemotherapy was completed in a median duration of 38.5 weeks. Administration of high dose methotrexate containing chemotherapy is feasible in pediatric patients with osteosarcoma, even in resource limited settings, if there are facilities for hydration, determination of methotrexate levels and good supportive care.

Prevalence and Risk Factors of Work Related Musculo Skeletal Disorders (WRMSD’s) Among Doctors - A Cross Sectional Study

Work related musculoskeletal disorders (WRMSDs) have not only shown to impact the physical and pschycological comfort of the employee but also deteriorate the prospects of any production or service sector. The prevalence of WRMSDs, though studied extensively in various sectors, has been understudied in health sector, especially among doctors. This study which evaluated the prevalence and risk factors of these disorders among fifty cancer treating Radiation Oncologist at a Tertiary Care Cancer Centre in India had exposed out an alarming 68% prevalence of these disorders in the study population, with neck pain being the commonest site of these Muscloskeletal Disorders (MSDs). Several factors which could impact the development of MSDs were analysed. This higher incidence of MSDs is presumed to be because of extreme physical and mental stress of working in a high volume cancer care centre, persistent unhealthy postures during work, inadequate micropauses between works and uncomfortable working atmosphere. Adequate physician patient ratio, restricting the patient load, providing good physician friendly working environment and adequate mandatory breaks might significantly reduce the incidence of these disorders and can prevent the sagging of health care delivery.

Colorectal Cancers in Low- and Middle-Income Countries-Demographic Pattern and Clinical Profile of 970 Patients Treated at a Tertiary Care Cancer Center in India.

PURPOSEGlobally, colorectal cancer (CRC) ranks third in terms of incidence and second in terms of mortality. A relatively low burden of CRC has been reported from low- and middle-income countries (LMIC), and there is a paucity of publications related to CRC from LMIC.PATIENTS AND METHODSA computerized comprehensive structured CRC clinical database was developed. All the patients with histopathologically proven CRC undergoing either curative and palliative multimodality management or surgical interventions between 2000 and 2019 were included in the study. A descriptive analysis of the demographic profile and clinical spectrum was performed.RESULTSA total of 970 patients of CRC were treated between 2000 and 2019. Of these, 401 patients (41.3%) had colon cancer and 569 (58.7%) had rectal cancer. The male-to-female ratio was 1.79:1. The mean age at presentation was 47.7 years. A total of 337 (34.7%) patients qualified as young CRC (≤ 40 years of age at diagnosis). The commonest symptom among patients with colon cancer was abdominal pain; 55.6% of patients had a right-sided primary tumor as compared with 42.2% with left-sided tumors. The commonest symptom among patients with rectal cancer was bleeding per rectum. The predominant location of the tumor was in the lower rectum (58%). Majority of patients with CRC presented with locally advanced stage II and III disease. The most common histologic subtype encountered for both colon and rectal cancers was adenocarcinoma (84.8% and 81.2%, respectively).CONCLUSIONThis study has revealed certain important findings related to CRC in LMIC including a higher burden of young colorectal cancer, a relatively higher proportion of rectal cancers in comparison with colon cancer, a high percentage of patients with low-rectal cancer, and advanced stage at presentation.

Prevalence and Risk Factors of work Related Musculo Skeletal Disorders (wrmsd’s) Among Doctors - A Cross Sectional Study

Work related musculoskeletal disorders (WRMSDs) have not only shown to impact the physical and pschycological comfort of the employee but also deteriorate the prospects of any production or service sector. The prevalence of WRMSDs, though studied extensively in various sectors, has been understudied in health sector, especially among doctors. This study which evaluated the prevalence and risk factors of these disorders among fifty cancer treating Radiation Oncologist at a Tertiary Care Cancer Centre in India had exposed out an alarming 68% prevalence of these disorders in the study population, with neck pain being the commonest site of these Muscloskeletal Disorders (MSDs). Several factors which could impact the development of MSDs were analysed. This higher incidence of MSDs is presumed to be because of extreme physical and mental stress of working in a high volume cancer care centre, persistent unhealthy postures during work, inadequate micropauses between works and uncomfortable working atmosphere. Adequate physician patient ratio, restricting the patient load, providing good physician friendly working environment and adequate mandatory breaks might significantly reduce the incidence of these disorders and can prevent the sagging of health care delivery.